From Exploitation to Ethics: The History of Human Subjects Research

Author: Lauren Carpenter, BS – Research Compliance Analyst

Scientific progress relies on studying human beings, but history shows that discovery can come at a severe ethical cost. The story of human subjects research is one of hard-learned lessons, evolving from exploitation to a strong system of ethics and regulations that now protect participants.

For most of history, medical research was conducted without ethical guidelines. Ancient Greek physicians like Hippocrates and Galen experimented to understand disease, but the idea that participants should give consent or even be informed about what was happening didn’t exist.

As medicine became more experimental in the 18th and 19th centuries, vulnerable populations often bore the burden. Prisoners, orphans, enslaved people, and the poor were used as test subjects without their consent. In the 1840s, James Marion Sims, often called the “father of modern gynecology,” performed painful surgeries on enslaved women without anesthesia.

The pursuit of knowledge was deemed so essential that it often overshadowed individuals’ rights, which frequently went unnoticed.

The early 1900s saw significant medical advances alongside concerning ethical breaches. Physicians deliberately infected patients, soldiers, and prisoners with diseases to study immunity, often without obtaining consent.

The most severe abuses occurred during World War II, when Nazi doctors carried out horrific experiments on prisoners in concentration camps. These atrocities directly contributed to the establishment of the Nuremberg Code in 1947, which was the first formal set of research ethics emphasizing the importance of voluntary consent and the right to withdraw from participation.

Despite advances in medical ethics, abuses persisted. The Tuskegee Syphilis Study (1932–1972) in the U.S. intentionally denied treatment to Black men with syphilis to observe the progression of the disease. During the Cold War, researchers exposed unsuspecting patients to radiation and conducted tests with chemical agents on soldiers and civilians. Public exposure of these cases in the 1960s and 1970s forced governments to act.

The U.S. National Research Act of 1974 created the framework for ethical oversight in federally funded research. It established the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, which produced the Belmont Report (1979), still the foundation of modern research ethics.

The Belmont Report defined three core principles:

1. Respect for Persons: Recognizing autonomy and protecting those with limited capacity.
2. Beneficence: Maximizing benefits and minimizing harm.
3. Justice: Ensuring fair distribution of research’s risks and benefits.

These principles became codified in U.S. law under the Common Rule (45 CFR 46), the central regulation governing human subjects research.

Today, ethical research is inseparable from regulatory compliance. Multiple layers of oversight ensure protection for human subjects:

Every U.S. institution conducting human subjects research must maintain an IRB. These committees review study protocols to ensure they meet ethical and regulatory standards before approval. IRBs verify that:

• Participants give informed consent,
• Risks are minimized and justified,
• Selection of subjects is fair, and
• Privacy and data protections are in place.

IRBs operate under the authority of the Office for Human Research Protections (OHRP) within the U.S. Department of Health and Human Services (HHS). Institutions engaged in federally funded research must file a Federal-wide Assurance (FWA) that commits them to comply with the Common Rule.

The U.S. Food and Drug Administration (FDA) regulates clinical trials involving drugs, biologics, and medical devices under 21 CFR Parts 50 and 56. While similar to the Common Rule, FDA regulations emphasize data integrity, safety monitoring, and good clinical practice (GCP).

Globally, research compliance follows principles established by the Declaration of Helsinki, Council for International Organizations of Medical Sciences (CIOMS) guidelines, and the International Council for Harmonisation (ICH) Good Clinical Practice framework. These standards align ethical expectations across borders, particularly important for multinational clinical trials.

Compliance doesn’t end with IRB approval. Institutions and sponsors are responsible for continuous oversight, including:

• Continuing review of ongoing studies,
• Adverse event reporting,
• Protocol deviation tracking, and
• Audits by internal compliance offices, OHRP, or the FDA.

Violations can lead to suspension of research, loss of funding, or even criminal penalties.

The history of human subjects research shows that ethical standards were not born from idealism but from outrage, loss, and reform. Compliance frameworks like the Common Rule and FDA regulations now formalize what should always have been true: science must serve humanity, not exploit it.

Every IRB review, consent form, and compliance audit is part of that legacy, a safeguard built from centuries of mistakes, ensuring that progress never again comes at the expense of human dignity.

The history of human subjects research shows how scientific progress and ethical safeguards can grow together. From unregulated experimentation to transparent, participant-centered research, this evolution offers valuable lessons for how AI can be developed responsibly while accelerating innovation.

Human subjects protections emphasized clear communication about what a study involves. AI can benefit from this same mindset. When an AI system explains its reasoning, users gain confidence in adopting new tools. Transparent design doesn’t hinder AI; it helps people rely on it more fully.

Ethical research requires weighing potential risks against expected benefits. Applied to AI, this encourages thoughtful testing rather than fear-based restriction. Developers already use extensive pre-deployment evaluations to refine systems before they reach the public. This mirrors the maturing process that made human subjects research safer and more effective over time.

Institutional Review Boards transformed research by adding structured review without stopping progress. AI is developing similar guardrails: model review boards, red-team evaluations, and continuous monitoring systems. These mechanisms draw directly from the research tradition, helping organizations innovate quickly while keeping ethical considerations in view.

Human subjects protections developed gradually as research grew more complex. AI is following a similar path improving through iteration, feedback, and broadened participation. The history of research ethics reminds us that thoughtful governance is not a brake on innovation; it’s part of how breakthrough technologies mature.

As this history shows, the path from exploitation to ethical oversight was neither quick nor easy, but it reshaped research into a discipline grounded in respect, transparency, and accountability. Those same principles now guide emerging fields like AI, reminding us that responsible innovation grows from the lessons of the past. By carrying forward the core values of human subjects protections, we can continue advancing science in ways that protect individuals, strengthen public trust, and ensure that new technologies truly serve the people they are meant to help.